Quick Facts / Company Snapshot
| Metric | Data Point |
| Company Name | Cryoport, Inc. |
| Ticker Symbol | CYRX |
| Stock Exchange | The NASDAQ Stock Market LLC |
| Total Revenue (2025) | $176,177,000 |
| Net Income (2025) | $78,301,000 |
| Operating Loss (2025) | $(36,806,000) |
| Total Assets (2025) | $764,989,000 |
| Total Liabilities (2025) | $262,351,000 |
| Total Stockholders’ Equity (2025) | $502,638,000 |
| Employee Count | 738 (684 full-time, 8 part-time, 46 temporary) |
| CEO and President | Jerrell W. Shelton |
| Headquarters | 112 Westwood Place, Suite 350, Brentwood, TN 37027 |
| State of Incorporation | Nevada |
| Year Founded | 1999 |
| Fiscal Year End | December 31 |
| Basic Earnings Per Share (2025) | $1.40 |
| Cash and Cash Equivalents (2025) | $250,494,000 |
| Outstanding Shares (Feb 27, 2026) | 49,856,135 |
| Total Debt (Convertible Senior Notes Net – 2025) | $185,094,000 |
| Life Sciences Services Revenue (2025) | $96,497,000 |
Company Overview
Cryoport, Inc. operates as a leading global provider of integrated, temperature-controlled supply chain solutions dedicated primarily to the life sciences industry. The enterprise places a strong operational focus on supporting the rapidly expanding cell and gene therapy market. Through a unified ecosystem of subsidiaries and proprietary technologies, the organization ensures the safe, regulatory-compliant storage, handling, and delivery of high-value, temperature-sensitive biological materials.
The organizational footprint supports a broad spectrum of global life sciences sectors. These include biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research facilities, and government agencies. Cryoport addresses the strict requirements of these markets through a combination of advanced logistics, biostorage, kitting and labeling, clinical sample management, and cryogenic systems manufacturing.
- The company supported 760 clinical trials globally as of December 31, 2025.
- A total of 86 of these clinical trials were in Phase III development.
- The organization currently supports 20 commercially approved cell and gene therapies.
- Revenue derived from the support of commercial cell and gene therapies reached $33.4 million in 2025.
A central pillar of the organizational strategy is the implementation of an end-to-end “Chain of Compliance.” This framework transcends traditional chain-of-custody and chain-of-condition tracking by embedding rigorous documentation, process control, and quality management into every physical and digital touchpoint. The infrastructure guarantees traceability and risk mitigation from the initial collection of materials through to final delivery at the point of care.
Business Segments
Segment Financial Overview
| Business Segment | Revenue (2025) | Percentage of Total Revenue |
| Life Sciences Services | $96,497,000 | 54.8% |
| Life Sciences Products | $79,680,000 | 45.2% |
| Total | $176,177,000 | 100.0% |
Life Sciences Services
The Life Sciences Services segment operates as the core logistical and storage framework of the organization. This unit is built upon three foundational pillars: the Cryoportal digital logistics management platform, the Chain of Compliance and quality principles, and the Global Supply Chain Center Network. The segment aggregates two operational areas: BioLogistics Solutions and BioStorage/BioServices.
This segment is heavily integrated with the clinical and commercial workflows of biotechnology and pharmaceutical entities. It facilitates the transport, storage, and specialized handling of highly fragile biological materials. The services provided are designed to eliminate risks associated with disjointed supply chains, ensuring that therapies maintain viability, identity, and quality during transit and holding.
- Life Sciences Services revenue increased by $14,453,000 or 17.6% year-over-year in 2025.
- Cost of services revenue stood at $49,429,000 in 2025, yielding a gross margin of 48.8%.
- The gross margin improvement was driven by a favorable revenue mix shift toward higher-margin BioServices and BioStorage offerings.
Life Sciences Products
The Life Sciences Products segment focuses entirely on the design and manufacturing of industry-leading cryogenic systems. This segment operates under the MVE Biological Solutions brand, utilizing manufacturing facilities in the United States and China. The products developed here serve as the physical foundation for the storage and movement of biological materials worldwide.
The equipment manufactured includes high-capacity liquid- and vapor-phase cryogenic freezers, self-sustaining freezers, and portable aluminum dewars. These systems are procured by biorepositories, clinical laboratories, research institutions, and in-vitro fertilization clinics to protect irreplaceable biological assets at strictly regulated temperatures.
- Life Sciences Products revenue increased by $4,955,000 or 6.6% year-over-year in 2025.
- Cost of products revenue was $43,694,000, achieving a gross margin of 45.2%.
- Revenue growth was primarily driven by increased demand in the EMEA and APAC regions, alongside strong animal health customer demand in the Americas.
History and Evolution
The enterprise was originally incorporated under the laws of the State of Nevada on May 25, 1990, under the name G.T.5-Limited. Cryoport Systems, Inc. was initially formed in 1999 as a California limited liability company and subsequently reorganized into a California corporation on December 11, 2000. In March 2005, through a Share Exchange Agreement, the organization changed its name to Cryoport, Inc. and acquired all issued and outstanding shares of Cryoport Systems, Inc.
The organizational trajectory shifted significantly in November 2012 when Jerrell W. Shelton was appointed President and Chief Executive Officer. Under his leadership, the organization expanded its technological capabilities and geographic footprint to target the regenerative medicine, animal health, and reproductive medicine markets. In October 2020, the organization completed a major strategic expansion by acquiring MVE Biological Solutions, significantly boosting its physical manufacturing capabilities for cryogenic systems.
- In November 2023, the organization acquired Tec4med, integrating next-generation condition monitoring and artificial intelligence solutions.
- During 2024, the Enterprise Technology Group was established to unify digital platforms and automation.
- On June 11, 2025, the organization completed the divestiture of its specialty courier CRYOPDP business to DHL for $133,000,000.
The divestiture of the CRYOPDP business marked a strategic shift to focus on high-value services and technologies. The transaction included the repayment of approximately $77,200,000 in outstanding intercompany loans. Following this divestiture, the organization initiated operations at a new Global Supply Chain Center in Paris, France, in November 2025, and secured an exclusive collaboration with Moffitt Cancer Center for BioStorage services.
Products and Services
Products and Services Revenue Breakdown
| Product / Service Category | Revenue (2025) | Percentage of Total Revenue |
| BioLogistics Solutions | $78,137,000 | 44.3% |
| Life Sciences Products | $79,680,000 | 45.2% |
| BioStorage/BioServices | $18,360,000 | 10.4% |
| Total | $176,177,000 | 100.0% |
(Note: Life Sciences Services total $96,497,000, derived from BioLogistics + BioStorage/BioServices. The percentage calculations are derived directly from the disclosed segment figures.)
Life Sciences Products (Cryogenic Systems Manufacturing)
This category represents the physical hardware manufactured by the organization. The product portfolio includes the MVE Series Freezers, which are liquid- and vapor-phase cryogenic units designed for high-capacity biological storage. The High-Efficiency Series offers advanced control systems for temperature monitoring at approximately -190°C. The portfolio also includes MVE Fusion Freezers, which are self-sustaining units that do not require a continuous liquid nitrogen supply.
The organization also manufactures the MVE Vario Cryogenic System, a configurable platform supporting temperatures ranging from -20°C to -150°C. For transportation, the portfolio includes lightweight aluminum dewars, vapor shippers featuring rapid charging technology, and Doble Series hybrid dewars that function as both transport and storage vessels.
- Revenue from the support of commercial cell and gene therapies within the Products segment reached $3,500,000 in 2025.
- The manufacturing line in Chengdu, China, was expanded in 2025, with full production expected to commence in the first quarter of 2026.
- All applicable MVE-manufactured cryogenic freezers and dewars are listed with the FDA.
BioLogistics Solutions
BioLogistics Solutions provide highly specific, temperature-controlled transportation services for cell and gene therapies and other critical biological materials. These services utilize purpose-built shipping systems alongside continuous condition monitoring and tracking. The solutions incorporate customs and trade compliance support, integrated logistics management, and consulting services to ensure reliable global transport.
A key component of this offering is the integration of cryopreservation services through the newly introduced IntegriCell platform. IntegriCell provides standardized, scalable cryopreservation and cryo-processing services for cellular starting materials, specifically targeting leukapheresis material collection.
- BioLogistics Solutions generated a 16.6% year-over-year revenue increase in 2025.
- Revenue from the support of commercial cell and gene therapies within BioLogistics reached $29,900,000.
- The IntegriCell platform operates from two purpose-built facilities located in Houston, Texas, and Liège, Belgium.
BioStorage/BioServices
The BioStorage and BioServices segment integrates temperature-controlled storage and value-added operations directly into client workflows. BioServices includes sterile and cGMP kit production, qualified person drug product release services, labeling, secondary packaging, order fulfillment, and clinical sample management. These services are specifically designed to scale alongside clients as therapies move from clinical development to commercialization.
BioStorage solutions, managed primarily through the CryoGene operations, focus on longer-term storage supporting preclinical and early-stage clinical trials. Operations are registered and accredited to applicable FDA, ISO, GMP, and tissue-handling standards.
- BioStorage/BioServices revenue experienced a 22.2% year-over-year growth in 2025.
- CryoGene operates facilities in Houston and San Antonio, Texas.
- A third biorepository is scheduled to open in Tampa, Florida, in mid-2027.
Brand Portfolio
Brand Revenue Overview
(Note: Brand-specific revenue is captured under the broader business segments; the organization does not disaggregate revenue strictly by individual trademarked brands, but allocates them to the segment revenues listed above. The following brands are the primary drivers of the $176,177,000 total revenue.)
MVE Biological Solutions
MVE Biological Solutions is the foundational manufacturing arm of the organization, possessing more than 65 years of experience in designing and producing cryogenic storage and transport systems. The brand is globally recognized for its stainless-steel freezers and aluminum dewars, which are certified to the Medical Device Directive in the European Union and registered with the FDA.
Cryoport Express® and ELITE™
The Cryoport Express® and ELITE™ brands encompass the specialized packaging and shipping systems used for transporting temperature-sensitive materials. The Cryoport Express Cryogenic HV3 Shipping System was launched to enhance payload protection and optimize storage efficiency. These shippers meet strict international regulations for the transport of dangerous goods and biological materials.
Cryoportal®
Cryoportal® serves as the digital platform and nerve center for the organization’s logistics network. It integrates with client and vendor systems through application programming interfaces, enabling seamless data exchange, real-time visibility, and comprehensive monitoring of the entire logistics process.
- The platform manages the end-to-end Chain of Compliance, ensuring adherence to ISO 21973:2020.
- It captures and aggregates environmental, shipping, biostorage, and handling data into unified records.
Tec4med & Smartpak®
Tec4med and Smartpak® represent the organization’s condition monitoring technologies. The Smartpak Condition Monitoring System provides real-time data tracking during transit. Tec4med, acquired in 2023, provides Internet of Things technology that specializes in real-time condition monitoring and data-driven traceability in the regulated life sciences.
IntegriCell®
Introduced in late 2024, IntegriCell® is the brand representing the organization’s cryopreservation services. It addresses the challenge of variability in leukapheresis starting materials by standardizing the collection and cryopreservation processes, thereby alleviating manufacturing bottlenecks for cell therapies.
CryoGene
CryoGene is the brand operating the biostorage operations within the Americas. It delivers long-term temperature-controlled biological storage and related value-added services, acting as a critical repository for preclinical and early-stage clinical programs.
Geographical Presence
Geographic Revenue Breakdown (By Origin)
| Region | Revenue (2025) | Percentage of Total Revenue |
| Americas | $131,260,000 | 74.5% |
| Europe, Middle East, and Africa (EMEA) | $25,134,000 | 14.3% |
| Asia-Pacific (APAC) | $19,783,000 | 11.2% |
| Total | $176,177,000 | 100.0% |
Americas Operations
The Americas represent the largest revenue-generating region for the organization, accounting for 74.5% of total revenue in 2025. The principal executive office is located in Brentwood, Tennessee. The region houses major administrative, research and development, and Global Supply Chain Centers.
Facilities include centers in Irvine, California; Morris Plains, New Jersey; and Houston, Texas. The Houston location operates as both a Global Supply Chain Center and a major biostorage hub. Manufacturing operations for MVE are located in Ball Ground, Georgia, and New Prague, Minnesota.
- Property and equipment assets located in the United States totaled $57,542,000 in 2025.
- A new Global Supply Chain Center is scheduled to open in Santa Ana, California, in late 2026.
- A third CryoGene biorepository is planned for Tampa, Florida, in mid-2027.
EMEA Operations
The EMEA region serves as a critical growth vector, contributing 14.3% to the total revenue. The organization maintains a robust network of Global Supply Chain Centers and bioservices facilities across Europe. Key locations include a new center in Louvres (Paris Area), France, which commenced BioLogistics services in November 2025.
Additionally, the organization operates a major bioservices, cryopreservation, and research center in Liège, Belgium. A global logistics center is situated in Hoofddorp, the Netherlands, and an administrative and bioservices facility is owned in Clermont-Ferrand, France.
- Property and equipment assets in Belgium totaled $12,108,000 in 2025.
- Property and equipment assets in France totaled $11,859,000 in 2025.
- BioServices operations in the Paris facility are expected to commence in the fourth quarter of 2026.
APAC Operations
The Asia-Pacific region accounted for 11.2% of the organization’s revenue in 2025. The footprint in this region is anchored by an owned administrative and manufacturing facility in Chengdu, China. This facility supports the production of cryogenic freezers and is a vital component of the global supply chain for the MVE Biological Solutions segment.
- The Chengdu manufacturing line was expanded in 2025 to increase production capacity.
- Production from this expanded line is expected to commence during the first quarter of 2026.
Profit and Loss
Consolidated Statements of Operations (Years Ended December 31)
| Metric (in thousands) | 2025 | 2024 | 2023 |
| Life sciences services revenue | $96,497 | $82,044 | $79,494 |
| Life sciences products revenue | $79,680 | $74,725 | $89,168 |
| Total revenue | $176,177 | $156,769 | $168,662 |
| Cost of services revenue | $49,429 | $43,564 | $41,226 |
| Cost of products revenue | $43,694 | $43,548 | $52,103 |
| Total cost of revenue | $93,123 | $87,112 | $93,329 |
| Gross margin | $83,054 | $69,657 | $75,333 |
| Selling, general and administrative | $102,819 | $109,809 | $108,261 |
| Engineering and development | $17,041 | $17,710 | $18,040 |
| Impairment loss | $— | $63,809 | $49,569 |
| Total operating costs and expenses | $119,860 | $191,328 | $175,870 |
| Loss from operations | $(36,806) | $(121,671) | $(100,537) |
| Investment income | $9,798 | $9,895 | $10,577 |
| Interest expense, net | $(2,361) | $(3,977) | $(5,580) |
| Gain on extinguishment of debt, net | $— | $18,505 | $5,679 |
| Other income (expense), net | $(2,801) | $(7,101) | $5,647 |
| Total other income, net | $4,636 | $17,322 | $16,323 |
| Loss from continuing ops before taxes | $(32,170) | $(104,349) | $(84,214) |
| Provision for income taxes | $(1,799) | $(359) | $(345) |
| Loss from continuing operations | $(33,969) | $(104,708) | $(84,559) |
| Income (loss) from discontinued ops | $112,270 | $(10,048) | $(15,028) |
| Net income (loss) | $78,301 | $(114,756) | $(99,587) |
| Paid-in-kind dividend on preferred | $(8,000) | $(8,000) | $(8,000) |
| Net income (loss) to stockholders | $70,301 | $(122,756) | $(107,587) |
Balance Sheet
Consolidated Balance Sheets (As of December 31)
| Assets (in thousands) | 2025 | 2024 |
| Cash and cash equivalents | $250,494 | $34,137 |
| Short-term investments | $160,714 | $216,460 |
| Accounts receivable, net | $33,359 | $25,304 |
| Inventories | $23,188 | $21,476 |
| Prepaid expenses and other current assets | $8,419 | $7,943 |
| Current assets held for sale | $— | $36,251 |
| Total current assets | $476,174 | $341,571 |
| Property and equipment, net | $85,448 | $80,013 |
| Operating lease right-of-use assets | $39,720 | $39,920 |
| Intangible assets, net | $138,082 | $147,927 |
| Goodwill | $22,400 | $20,569 |
| Deposits | $2,092 | $1,951 |
| Deferred tax assets | $1,073 | $842 |
| Long-term assets held for sale | $— | $70,699 |
| Total assets | $764,989 | $703,492 |
| Liabilities and Stockholders’ Equity (in thousands) | 2025 | 2024 |
| Accounts payable and other accrued expenses | $15,283 | $15,895 |
| Accrued compensation and related expenses | $12,980 | $11,209 |
| Deferred revenue | $943 | $1,061 |
| Current portion of operating lease liabilities | $4,133 | $3,399 |
| Current portion of finance lease liabilities | $422 | $315 |
| Current portion of convertible senior notes, net | $185,094 | $14,298 |
| Current portion of notes payable | $163 | $143 |
| Current portion of contingent consideration | $— | $2,808 |
| Current liabilities held for sale | $— | $15,435 |
| Total current liabilities | $219,018 | $64,563 |
| Convertible senior notes, net of current portion | $— | $183,919 |
| Notes payable, net of current portion | $1,087 | $1,114 |
| Operating lease liabilities, net of current portion | $39,078 | $38,551 |
| Finance lease liabilities, net of current portion | $741 | $800 |
| Deferred tax liabilities | $1,354 | $804 |
| Other long-term liabilities | $444 | $295 |
| Contingent consideration, net of current portion | $629 | $3,751 |
| Long-term liabilities held for sale | $— | $7,797 |
| Total liabilities | $262,351 | $301,594 |
| Total stockholders’ equity | $502,638 | $401,898 |
| Total liabilities and stockholders’ equity | $764,989 | $703,492 |
Cash Flow
Consolidated Statements of Cash Flows (Years Ended December 31)
| Cash Flows (in thousands) | 2025 | 2024 | 2023 |
| Net income (loss) | $78,301 | $(114,756) | $(99,587) |
| Depreciation and amortization | $27,712 | $30,757 | $27,487 |
| Impairment loss | $— | $63,809 | $49,569 |
| Gain on divested business | $(116,953) | $— | $— |
| Stock-based compensation expense | $11,032 | $19,704 | $22,808 |
| Changes in operating assets and liabilities | $(8,672) | $(15,837) | $(1,034) |
| Net cash used in operating activities | $(8,580) | $(16,323) | $(757) |
| Purchases of property and equipment | $(16,439) | $(17,254) | $(38,785) |
| Proceeds from divested business | $210,239 | $— | $— |
| Sales/maturities of short-term investments | $59,589 | $249,116 | $129,987 |
| Purchases of short-term investments | $— | $(50,721) | $(42,677) |
| Net cash provided by investing activities | $250,323 | $176,815 | $36,045 |
| Repurchase of common stock | $(10,011) | $— | $— |
| Cash paid for repurchase of 2026 Notes | $— | $(163,772) | $(25,003) |
| Repayment of 2025 Convertible Senior Notes | $(14,344) | $— | $— |
| Net cash used in financing activities | $(21,074) | $(161,531) | $(23,798) |
| Effect of exchange rates on cash | $(15,464) | $(18) | $(1,739) |
| Net change in cash and cash equivalents | $205,205 | $(1,057) | $9,751 |
Board of Directors and Leadership Team
Jerrell W. Shelton
Mr. Shelton serves as the President and Chief Executive Officer and holds the position of Chairman of the Board. He was appointed to the board in October 2012 and assumed the CEO role shortly thereafter. His leadership history includes serving as Chairman and CEO of Wellness, Inc., and as Visiting Executive to IBM Research. He holds a B.S. in Business Administration from the University of Tennessee and an M.B.A. from Harvard University. His extensive strategic planning and financial expertise guide the organizational direction.
Robert S. Stefanovich
Mr. Stefanovich has been the Chief Financial Officer and Treasurer since June 2011, taking on the additional title of Senior Vice President in 2019. He previously served as CFO of Novalar Pharmaceuticals, Inc., and held senior leadership roles at Xcorporeal, Inc., and Artemis International Solutions Corporation. He received his Master of Business Administration and Engineering from the University of Darmstadt, Germany.
Mark Sawicki, Ph.D.
Dr. Sawicki serves as the Senior Vice President and Chief Scientific Officer of the organization, and acts as the President and Chief Executive Officer of Cryoport Systems, LLC. He joined the organization in 2015 as Chief Commercial Officer. Dr. Sawicki holds a Ph.D. in biochemistry from the State University of New York at Buffalo. He has a deep background in business development within the pharmaceutical and biotechnology industries.
Edward J. Zecchini
Mr. Zecchini was appointed Chief Digital and Technology Officer in February 2024. Prior to this executive role, he served as a member of the Board of Directors from 2013 through 2024. He brings over thirty years of experience in healthcare and information technology, having previously served as Chief Information Officer at Remedy Partners, Inc.
Daniel M. Hancock
Mr. Hancock serves as an independent Director on the board. His professional background and oversight contribute to the governance and strategic direction of the enterprise.
Robert Hariri, M.D., Ph.D.
Dr. Hariri serves as a Director, bringing extensive medical and scientific expertise to the board. His background supports the organization’s strategic alignment with the advanced therapies and biotechnology markets.
Ramkumar Mandalam, Ph.D.
Dr. Mandalam sits on the Board of Directors. His insights assist the organization in navigating the highly technical and regulated environment of biomanufacturing and life sciences supply chains.
Ram Jagannath
Mr. Jagannath serves as a Director, nominated by funds affiliated with The Blackstone Group. He provides significant financial and investment oversight, representing a major institutional stakeholder.
Linda Baddour
Ms. Baddour is a member of the Board of Directors. She brings executive-level financial and operational experience to the board, assisting in corporate governance and financial strategy.
Subsidiaries, associates, joint ventures
Disclosed Operating Entities
| Subsidiary / Entity | Revenue (2025) | Percentage of Total Revenue | Operational Scope |
| Cryoport Systems, LLC | $96,497,000 | 54.8% | BioLogistics, BioStorage, and BioServices operations. |
| MVE Biological Solutions | $79,680,000 | 45.2% | Cryogenic systems manufacturing and design. |
| CryoGene | Not Disaggregated | N/A | Operates within BioStorage under Life Sciences Services. |
| Tec4med | Not Disaggregated | N/A | Provides IoT and condition monitoring hardware/software. |
| Cryoport Netherlands BV | Not Disaggregated | N/A | Facilitates European logistics and supply chain operations. |
| Cryoport Germany GmbH | Not Disaggregated | N/A | Manages operations and assets within the German market. |
(Note: Revenue for Cryoport Systems corresponds with the total Life Sciences Services segment, while MVE corresponds with the Life Sciences Products segment. Sub-brands like CryoGene and Tec4med are rolled into these reporting units.)
Cryoport Systems, LLC
Originally formed as a California LLC in 1999, this entity was acquired by the parent organization in 2005. It serves as the primary operational vehicle for the organization’s temperature-controlled logistics, biostorage, and bioservices. The subsidiary manages the global network of supply chain centers and deploys the Cryoportal and Cryoport Express systems.
MVE Biological Solutions
Acquired in 2020, MVE operates as the principal manufacturing subsidiary. It designs and produces the physical freezers and aluminum dewars required by the life sciences industry. MVE maintains manufacturing facilities in the United States and China and is heavily integrated into the organization’s comprehensive “Chain of Compliance.”
Other Investments (Including Minority / Portfolio Holdings)
Short-Term Financial Investments
| Investment Type | Fair Value (2025) | Percentage of Short-Term Investments |
| Mutual funds | $99,182,000 | 61.7% |
| Corporate debt securities | $41,694,000 | 25.9% |
| U.S. Treasury notes and bills | $19,838,000 | 12.4% |
| Total | $160,714,000 | 100.0% |
The organization does not disclose specific minority equity stakes in other operating companies or strategic joint ventures within its 2025 financial statements. Instead, the organization maintains a robust portfolio of available-for-sale and equity investments aimed at enhancing overall returns while ensuring the safety of principal.
- Mutual funds held by the organization invest primarily in tax-free municipal bonds and treasury inflation-protected securities.
- Corporate debt securities are classified as available-for-sale and are carried at fair value.
- The total fair value of these short-term investments stood at $160,714,000 as of December 31, 2025.
Physical properties
The organization manages a global physical infrastructure comprising 20 sites across the Americas, EMEA, and APAC regions. These locations support corporate administration, logistics, biostorage, manufacturing, and research and development.
- Brentwood, Tennessee: Serves as the Principal Executive Office under a leased arrangement.
- Irvine, California: Operates as an administrative hub, Global Supply Chain Center, and Research and Development Center (Leased).
- Morris Plains, New Jersey: Functions as a Global Supply Chain Center and administrative office (Leased).
- Houston, Texas: Acts as a major Global Supply Chain Center and Biostorage Center (Leased).
- Louvres (Paris Area), France: A newly established Global Supply Chain Center (Leased).
- Liège, Belgium: Dedicated to Bioservices, Cryopreservation (IntegriCell), and Research and Development (Leased).
- Hoofddorp, the Netherlands: Serves as a Global Logistics Center (Leased).
- Ball Ground, Georgia: Houses administrative, manufacturing, and Research and Development operations (Leased).
- New Prague, Minnesota: An owned manufacturing facility supporting MVE Biological Solutions.
- Chengdu, China: An owned administrative and manufacturing facility.
- Clermont-Ferrand, France: An owned facility dedicated to administrative and bioservices operations.
Founders
Cryoport was originally founded in 1999 as a California limited liability company before undergoing corporate reorganization. While the original founders of the parent company are not explicitly detailed in recent reports, the organization highlights the founders of its acquired technologies.
Specifically, Tec4med, which was acquired by Cryoport Systems in November 2023, was founded in 2017 by Nico Höler and Julian Poths. It originated as a technology spin-off from the Technical University of Darmstadt, Germany, bringing critical condition monitoring and AI solutions to the organization.
Parent
Cryoport, Inc. operates as the ultimate parent company. It is a publicly traded entity incorporated in the State of Nevada, and its common stock is listed on the NASDAQ Capital Market under the ticker symbol CYRX. The organization oversees its wholly-owned subsidiaries, including Cryoport Systems, LLC and MVE Biological Solutions, without any superior parent entity dictating its operations.
Investments and capital expenditure plans
The organization actively reinvests in its infrastructure and technological capabilities to meet the growing demands of the cell and gene therapy market. Capital expenditures are directed toward facility expansion, software development, and the expansion of the physical shipping fleet.
- During 2025, the organization utilized $16,439,000 for the purchase of property and equipment.
- Investments included facility expansions, leasehold improvements, and the acquisition of additional Cryoport Express Shippers and freezers.
- Software development costs totaled $1,832,000 in 2025, supporting the ongoing enhancement of the Cryoportal platform.
- The organization reported $18,089,000 in fixed assets in process at year-end, primarily relating to facility expansions in the United States, Belgium, and France.
- Future capital plans include opening a new Global Supply Chain Center in Santa Ana, California, in late 2026, and a third CryoGene biorepository in Tampa, Florida, in mid-2027.
Shareholding pattern
The organizational capitalization structure involves both common stock and specialized preferred equity classes. As of February 27, 2026, there were 49,856,135 shares of common stock outstanding. The ownership landscape includes significant institutional backing and insider holdings.
- Directors, executive officers, and beneficial owners holding 10% or more of the outstanding common stock beneficially owned 12,203,384 shares, representing approximately 23.0% of the company.
- Funds affiliated with The Blackstone Group hold 200,000 shares of Series C Convertible Preferred Stock.
- The Series C Preferred Stock grants Blackstone customary registration rights, the right to nominate one board member, and the ability to convert shares into common stock at $38.6152 per share.
- The organization engaged in active share repurchases, utilizing $10,011,000 in 2025 to buy back 1,340,608 shares of common stock on the open market.
Future strategy
The future strategy of the organization is strictly aligned with the commercial expansion of the global cell and gene therapy market. Management intends to scale operations to support the transition of clinical pipeline therapies into globally commercialized treatments.
- The organization will leverage its Enterprise Technology Group (ETG) to deploy artificial intelligence and advanced analytics across its digital framework.
- Management plans to introduce the proprietary MVE CryoVerse Ecosystem in 2026, delivering real-time cloud visibility for cryogenic storage systems.
- The business strategy involves expanding the Global Supply Chain Center Network to ensure reliable coverage across major global markets, mitigating physical logistical bottlenecks.
- The IntegriCell platform will be aggressively expanded to standardize the collection and cryopreservation of leukapheresis materials for biopharma clients.
Key strengths
- Embedded Market Position: The organization supports 760 clinical trials and 20 commercially approved cell and gene therapies, demonstrating a deeply integrated relationship with life science developers.
- Regulatory Leadership: The organization holds certifications for ISO 9001:2015, ISO 13485:2016, and was the first globally to be certified to ISO 21973:2020 for the transportation of cells for therapeutic use.
- Comprehensive Technology Platform: The Cryoportal digital platform, combined with Smartpak and Tec4med condition monitoring, provides unmatched real-time data visibility and Chain of Compliance tracking.
- Manufacturing Independence: Through MVE Biological Solutions, the organization controls the manufacturing of its cryogenic storage systems, buffering it against external hardware supply chain shocks.
Key challenges and risks
- Macroeconomic and Trade Vulnerabilities: The organization is exposed to the risks of foreign currency fluctuations, inflationary pressures, and changes in global trade policies, including tariffs imposed between the U.S., China, and the EU.
- Component Sourcing Risks: The manufacturing of specialized cryogenic systems and data loggers relies on certain single-source suppliers, creating vulnerabilities to labor strikes, natural disasters, or geopolitical disruptions.
- Cybersecurity Threats: As the organization aggregates massive amounts of sensitive supply chain data and personal information within the Cryoportal, it faces constant and escalating risks from ransomware, malware, and data breaches.
- Debt Servicing: The organization carries a substantial amount of indebtedness, including $186,185,000 in 2026 Convertible Senior Notes. Servicing this debt requires dedicated cash flows and exposes the company to refinancing risks.
- Regulatory Compliance Complexity: Transporting dangerous goods and biological materials requires strict adherence to shifting regulations governed by the FDA, CDC, IATA, and various international bodies. Non-compliance could result in severe operational shutdowns and penalties.
Conclusion and strategic outlook
Cryoport, Inc. has aggressively transformed itself into the definitive backbone for the temperature-controlled life sciences supply chain. The strategic divestiture of the CRYOPDP courier business in 2025 allowed the organization to cleanly pivot its resources toward high-margin bioservices, technological automation, and cryogenic manufacturing.
By deeply embedding its services into the development workflows of 760 clinical trials, the organization has effectively secured future commercial revenue streams as these therapies gain regulatory approval. The introduction of the IntegriCell platform and the upcoming MVE CryoVerse Ecosystem reflect a proactive approach to solving industry bottlenecks before they threaten patient outcomes. Supported by a robust cash position of $250,494,000 and the continuous expansion of its global footprint, the organization is strategically calibrated to scale proportionately with the explosive growth projected for the advanced therapies sector.
FAQ section
What is the primary business of Cryoport, Inc.?
Cryoport provides integrated, temperature-controlled supply chain solutions for the life sciences industry, specializing in the logistics, biostorage, and bioservices required for highly sensitive cell and gene therapies.
How much revenue did Cryoport generate in 2025?
The company generated a total revenue of $176,177,000 in 2025, which represents a 12.4% increase compared to the previous year.
What are Cryoport’s main business segments?
The business operates through two primary segments: Life Sciences Services, which generated $96,497,000 in 2025, and Life Sciences Products (MVE Biological Solutions), which generated $79,680,000.
How many clinical trials does Cryoport support?
As of December 31, 2025, the company supported 760 clinical trials globally, including 86 trials in Phase III development.
Who is the CEO of Cryoport?
Jerrell W. Shelton serves as the President and Chief Executive Officer, a role he has held since 2012.
What was the result of the CRYOPDP divestiture?
In June 2025, Cryoport sold its specialty courier CRYOPDP business to DHL for $133,000,000. This divestiture generated a net gain of $116,953,000 and allowed the company to focus on high-value services and products.
Does Cryoport manufacture its own equipment?
Yes. Through its subsidiary MVE Biological Solutions, the company designs and manufactures cryogenic systems, freezers, and aluminum dewars at facilities in the United States and China.
What is the IntegriCell platform?
Introduced in late 2024, IntegriCell provides standardized, scalable cryopreservation and cryo-processing services for cellular starting materials, specifically targeting leukapheresis material collection.
Where is Cryoport headquartered?
The principal executive offices are located at 112 Westwood Place, Suite 350, Brentwood, Tennessee.
What is the company’s ticker symbol?
The company’s common stock trades on The NASDAQ Stock Market LLC under the ticker symbol CYRX.
Official Site: https://www.cryoport.com
Source: Content on FirmsWorld.com is based on publicly available corporate filings, regulatory disclosures, annual reports, SEC 10-K filings, investor relations materials, and, where applicable, direct communications with the company.
